ImmunoCellular Therapeutics, Ltd.
(NYSE Amex Equities : IMUC)

( )
IMUC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Loading IMUC News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.64%68.221.0%$511.57m
AMGNAmgen Inc.
-0.06%164.611.2%$473.08m
BIIBBiogen Inc.
-2.41%279.981.2%$433.18m
CELGCelgene Corporation
-0.26%125.201.1%$368.74m
REGNRegeneron Pharmaceuticals, Inc.
-0.25%371.392.7%$306.45m
VRTXVertex Pharmaceuticals Incorporated
-0.79%116.341.8%$289.18m
INCYIncyte Corporation
-1.05%123.082.1%$252.04m
ALXNAlexion Pharmaceuticals, Inc.
0.15%120.731.6%$213.99m
ILMNIllumina, Inc.
1.70%184.583.3%$188.12m
TSROTESARO, Inc.
2.58%142.0115.3%$145.06m
NBIXNeurocrine Biosciences, Inc.
-0.63%53.284.5%$109.21m
BMRNBioMarin Pharmaceutical Inc.
2.00%96.074.3%$103.70m
KITEKite Pharma, Inc.
2.77%82.8015.6%$98.74m
CLVSClovis Oncology, Inc.
1.35%58.6418.2%$88.77m
AAgilent Technologies, Inc.
0.06%54.841.6%$88.10m

Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.